BMRA · XBRL financial data

Biomerica financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BMRA's year ends in late May)

In thousands of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Revenue	1,567	1,017	1,116*	1,807	1,636	1,119	749*	1,380	1,210	987	875*	1,265
Revenue from contracts with customers	1,567	1,017	1,116*	1,807	1,636	1,119	749*	1,380	1,210	987	875*	1,265
Cost of revenue	1,242	1,166	1,096*	1,518	1,199	1,100	993*	956	1,159	1,031	946*	1,162
Gross profit	325	(149)	20*	289	437	19	(244)*	424	51	(44)	(71)*	103
Research and development	412	343	265*	297	257	217	252*	212	193	178	205*	206
Selling, general and administrative	1,521	1,508	1,283*	1,360	1,173	1,012	1,068*	1,330	1,231	1,076	1,257*	1,124
General and administrative	—	—	year only	—	739	686	692*	—	769	661	876*	—
Total operating expenses	1,933	1,851	1,548*	1,657	1,430	1,229	1,320*	1,542	1,424	1,254	1,462*	1,330
Operating income (loss)	(1,608)	(2,000)	(1,528)*	(1,368)	(993)	(1,210)	(1,564)*	(1,118)	(1,373)	(1,298)	(1,533)*	(1,227)
Other income (expense)	—	—	—	—	—	43	—	—	—	(6)	—	—
Income tax expense (benefit)	8	4	7*	4	(3)	(4)	5*	3	5	8	6*	6
Net income (loss)	(1,507)	(1,918)	(1,421)*	(1,316)	(950)	(1,163)	(1,544)*	2	(1,320)	(1,312)	(1,145)*	(1,232)
Earnings per share, basic USD per share	(0.09)	(0.11)	(0.08)*	(0.08)	(0.06)	(0.06)	—	0.00	(0.45)	(0.44)	(0.37)*	(0.37)
Earnings per share, diluted USD per share	(0.09)	(0.11)	(0.08)*	(0.08)	(0.06)	(0.06)	—	0.00	(0.45)	(0.44)	(0.37)*	(0.37)
Weighted average shares, basic thousands of shares	16,822	16,822	16,822*	16,822	17,121	19,186	—	2,639	2,908	3,010	3,105*	3,296
Weighted average shares, diluted thousands of shares	16,822	16,822	16,822*	16,822	17,121	19,186	—	2,639	2,908	3,010	3,105*	3,296

Balance sheet

CSV

Fiscal quarters (BMRA's year ends in late May)

In thousands of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Cash and cash equivalents	7,134	5,319	4,170	2,820	2,372	3,058	2,399	3,053	2,543	1,336	1,308	2,733
Accounts receivable	1,067	1,130	947	1,551	1,326	1,268	731	1,205	947	941	785	897
Inventory	1,841	2,129	2,376	1,942	1,789	1,655	1,490	1,473	1,524	1,645	1,707	1,634
Prepaid and other current assets	223	268	238	132	458	223	255	168	177	201	216	145
Total current assets	10,265	8,846	7,731	6,445	5,945	6,204	4,875	5,899	5,191	4,123	4,016	5,409
Property and equipment, net	210	194	201	184	167	151	135	120	105	91	78	68
Right-of-use asset	891	817	742	666	588	509	429	347	264	179	1,873	1,809
Total assets	11,831	10,342	9,254	7,870	7,274	7,376	5,945	6,854	6,034	4,878	6,759	8,071
Accounts payable	—	—	288	—	—	—	295	—	—	—	377	—
Accrued liabilities	—	—	850	—	—	—	377	—	—	—	794	—
Total current liabilities	1,822	1,991	2,204	2,151	1,876	1,649	1,740	1,693	1,599	1,561	2,481	2,837
Lease liability, non-current	626	543	459	373	284	193	100	6	—	—	1,648	1,586
Total liabilities	2,448	2,534	2,663	2,524	2,160	1,842	1,840	1,699	1,599	1,561	4,129	4,423
Accumulated deficit	(44,856)	(46,774)	(48,195)	(49,511)	(50,461)	(51,624)	(53,168)	(53,166)	(54,486)	(55,798)	(56,943)	(58,175)
Total stockholders' equity	9,383	7,808	6,591	5,346	5,114	5,534	4,105	5,155	4,435	3,317	2,630	3,648
Total liabilities and equity	11,831	10,342	9,254	7,870	7,274	7,376	5,945	6,854	6,034	4,878	6,759	8,071
Common shares outstanding (cover page) thousands of shares	16,822	16,822	16,822	16,822	18,337	20,366	2,815	2,870	3,020	3,090	4,589	4,599

Cash flows

CSV

Fiscal quarters (BMRA's year ends in late May)

In thousands of dollars	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25Nov 30, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 31, 2025	Q1 FY26Aug 31, 2025	Q2 FY26Nov 30, 2025	Q3 FY26Feb 28, 2026	Q4 FY26May 31, 2026	Q1 FY27Aug 31, 2026
Net income (loss)	(1,507)	(1,918)	(1,421)*	(1,316)	(950)	(1,163)	(1,544)*	2	(1,320)	(1,312)	(1,145)*	(1,232)
Stock-based compensation	122*	341*	204*	77	155*	120*	108*	133	117*	135*	91*	134
Net cash from operating activities	(842)*	(1,801)*	(1,044)*	(1,344)	(791)*	(1,045)*	(661)*	(268)	(991)*	(1,250)*	(912)*	(802)
Purchases of property and equipment	6*	0*	24*	—	—	—	—	—	—	—	—	—
Net cash from investing activities	(12)*	(16)*	(24)*	—	—	(4)*	0*	—	—	—	18*	—
Proceeds from issuing common stock	—	—	—	—	—	1,751*	0*	939	493*	63*	379*	2,231
Net cash from financing activities	—	—	year only	—	—	1,736*	(5)*	920	482*	61*	871*	2,231
Net change in cash	(854)*	(1,815)*	(1,149)*	(1,350)	(448)*	686*	(658)*	654	(510)*	(1,207)*	(28)*	1,425

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.